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Background
Elevated ALT values are frequently observed in HIV-
mono-infected patients. Recent studies have reported
cases of cryptogenic liver cirrhosis in HIV+ individuals.
Other possible explanations are non-alcoholic/alcoholic
steatohepatitis and drug toxicity. We have used two non-
invasive methods, liver elastometry (FibroScan) and a
serologic fibrosis index (FIB-4), for liver fibrosis screening
in a single centre.
Methods
HIV-infected patients without hepatitis B and C co-infec-
tion with at least one elevated ALT in 2007/2008 (males
>50 U/l, females >35 U/l) were selected for liver elastom-
etry by FibroScan (Echosens, Paris). Antiretroviral medi-
cation, co-medication, alcohol consumption, smoking,
recreational drug use and BMI were assessed. Liver stiff-
ness was classified as <7.2 kPa (no/minimal fibrosis),
7.2–12.5 kPa (moderate fibrosis), >12.5 -17.6 kPa (severe
fibrosis), >17.6 kPa (cirrhosis). FibroScans were per-
formed by two trained and experienced investigators
(high inter-observer-correlation, r = 0.80, p < .05). FIB-4
index (age[years] × AST[U/l])/(platelets [10^9/l] ×
ALT^0.5 [U/l]) was used for serologic fibrosis assessment.
For statistical evaluation, SPSS 15.0 was used.
Summary of results
Out of 1,098 HIV-infected individuals, 227 had increased
ALT without hepatitis co-infection; 81 patients were con-
secutively screened by FibroScan. A valid elastometry was
obtained in 79/81 (98%) patients. 76/81 were male,
median age was 45 years (27–71 years), median BMI 24.6
kg/sqm (19.1–33.7 kg/sqm), median ALT 60 U/l (38–144
U/l). 70/81 (86%) were on antiretroviral therapy with
median duration of 76 months. HIV-RNA was <40 copies/
ml in 63/70 treated patients (90%). Median CD4+ cells
were 618/μl (130–1635 cells/μl). Alcohol consumption
was >24 g/day (males) or >12 g/day (females) in 11% of
patients, 41% were smokers, and 17% reported consump-
tion of recreational drugs. Median liver stiffness was 5.2
kPa (3.1 – 8.8 kPa). No/minimal fibrosis was found in 70/
79 (89%), moderate fibrosis in 9/79 (11%). No patient
had severe fibrosis or cirrhosis. With FIB-4 62/81 (77%)
patients had no/minimal fibrosis, 18/81 (22%) moderate
fibrosis and 1/81 (1%) advanced fibrosis.
Conclusion
In this ongoing study about 20% of HIV-mono-infected
patients had elevated ALT. Advanced liver fibrosis was rare
in this cohort of HIV-mono-infected individuals, and
there is good agreement between FibroScan and FIB-4.
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